Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

 

 

Webcasts

11-09-2020

Reata Pharmaceuticals Third Quarter Financial Results and Update on Development Programs

Webcast: click here

Press (11-09-2020): 
Reata Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs

Press (11-09-2020): 
Reata Announces Positive Results From Year 2 of the Pivotal Phase 3 CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome

Teleconference Information

Date: Monday, November 09, 2020
Time: 08:00 am ET
Audience Dial-in (toll-free): (844)348-3946
Audience Dial-in (international): (213)358-0892
Access Code: 2896858

Read more
 MP3
 PDF

08-10-2020

Reata Pharmaceuticals Second Quarter Financial Results and Update on Development Programs

Webcast: click here

Press (08-10-2020): 
Reata Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs

Press (08-03-2020): 
Reata Pharmaceuticals, Inc. to Report Second Quarter 2020 Financial Results and to Provide an Update on Development Programs on August 10, 2020

Teleconference Information

Date: Monday, August 10, 2020
Time: 08:30 am ET
Audience Dial-in (toll-free): (800) 708-4539
Audience Dial-in (international): (847) 619-6396
Access Code: 49873533

Read more
 MP3
 PDF

06-11-2020

Reata Pharmaceuticals and Blackstone Life Sciences Announce $350 Million Strategic Investment

Webcast: click here

Press (06-11-2020): 
Reata Pharmaceuticals, Inc. and Blackstone Life Sciences Announce $350 Million Strategic Investment

Teleconference Information

Date: Thursday, June 11, 2020
Time: 08:30 am ET
Audience Dial-in (toll-free): (844) 348-3946
Audience Dial-in (international): (213) 358-0892
Access Code: 3371798

Read more
 MP3

Events and Presentations

10-22-2020

2020 ASN Poster

Poster: Prasad Devarajan, M.D., Cincinnati Children's Hospital, OH, USA, presented KIDNEYCODE: A Genetic Testing Program for Patients with Chronic Kidney Disease. 

 PDF

09-29-2020

Presentation of Results from the MOXIe Part 2 Study, by Dr. David Lynch

 PDF

08-2020

Corporate Presentation

 PDF

06-07-2020

2020 ERA-EDTA Posters

Poster: Colin J. Meyer, M.D., Reata Pharmaceuticals, European Renal Association–European Dialysis and Transplant Association, Milan, Italy, presented Kidney Effects in the MOXIeTrial: A Study of Omaveloxolone in Patients with Friedreich’s Ataxia

Poster: Prasad Devarajan, M.D., Reata Pharmaceuticals Consultant, European Renal Association–European Dialysis and Transplant Association, Milan, Italy, presented KIDNEYCODE: A Genetic Testing Program for Patients with Chronic Kidney Disease

Poster: R.J. White, MD, Ph.D., Reata Pharmaceuticals Investigator, European Renal Association–European Dialysis and Transplant Association, Milan, Italy, presented Application of a Risk-Mitigation Strategy to Prevent Excess Heart Failure Risk in Pulmonary Hypertension: LARIAT Study

Read more
 PDF

Vineet Jindal

Vineet Jindal

Vice President, Investor
Relations & Corporate
Communications

 (855) 55-REATA